Differential serum neutralisation of omicron sublineages in patients receiving prophylaxis with tixagevimab–cilgavimab

[...]the use of this approach depends on the SARS-CoV-2 variant.1 Because of the rapidly changing variants, in-vitro neutralisation data using relative fold-changes in effective concentration (EC50) are frequently used to decide whether a given monoclonal antibody will be effective for a variant.2 H...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The Lancet infectious diseases 2023-05, Vol.23 (5), p.528-530
Hauptverfasser:	Solera, Javier T, Arbol, Berta G, Ferreira, Victor H, Kurtesi, Alexandra, Hu, Queenie, Ierullo, Matthew, Valverde-Zuniga, Adriana, Raslan, Ismail, Nasir, Asma, Grizales, Clara, Hardy, W Rod, Kulasingam, Vathany, Gingras, Anne-Claude, Humar, Atul, Kumar, Deepali
Format:	Artikel
Sprache:	eng
Schlagworte:	Antibodies, Monoclonal Clinical trials Coronaviruses Correspondence COVID-19 Humans Immunity Infections Infectious diseases Monoclonal antibodies Neutralization Prophylaxis Public health SARS-CoV-2 - drug effects Severe acute respiratory syndrome coronavirus 2 Vaccination
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!